Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02375672 · ClinicalTrials.gov registry record · Phase 2
Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
A Phase 2 study, sponsored by Hoosier Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT02375672: Completed Phase 2 study, sponsored by Hoosier Cancer Research Network.
NCT02375672 is a Phase 2 study that has completed, run by Hoosier Cancer Research Network. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02375672, a Phase 2 study, has completed, sponsored by Hoosier Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a multi-institutional, single arm, open-label, phase II study, including a safety run-in cohort. No randomization or blinding involved.
Primary Outcome
Determine if pembrolizumab (MK-3475) in combination with chemotherapy improves median progression free survival (mPFS) compared to historical standards. Response Criteria - Evaluation of target lesions Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference
Interventions
- DRUG Pembrolizumab
- DRUG mFOLFOX6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-05-28 |
| Est. Completion | 2020-10-08 |
| Phase | Phase 2 |
What the finished NCT02375672 record still lists
NCT02375672 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02375672 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02375672 about?
NCT02375672 is a clinical study titled "Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer". This is a multi-institutional, single arm, open-label, phase II study, including a safety run-in cohort. No randomization or blinding involved.
What is the current status of trial NCT02375672?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2015-05-28. Estimated completion is 2020-10-08.
What interventions are being tested in trial NCT02375672?
The interventions under investigation include: Pembrolizumab (DRUG), mFOLFOX6 (DRUG).
Who is sponsoring clinical trial NCT02375672?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02375672's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI